These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

939 related items for PubMed ID: 19960016

  • 21. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker adherence in patients with primary versus secondary diagnosis of heart failure.
    Brackbill ML, Bashaw-Keaton R, Sytsma CS.
    Am J Manag Care; 2007 Oct; 13(10):568-70. PubMed ID: 17927461
    [Abstract] [Full Text] [Related]

  • 22. Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors.
    Setoguchi S, Levin R, Winkelmayer WC.
    Int J Cardiol; 2008 Apr 10; 125(2):172-7. PubMed ID: 17997175
    [Abstract] [Full Text] [Related]

  • 23. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA, Molnar J, Arora RR.
    Diabetes Obes Metab; 2008 Jan 10; 10(1):41-52. PubMed ID: 18095949
    [Abstract] [Full Text] [Related]

  • 24. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
    Gotsman I, Rubonivich S, Azaz-Livshits T.
    Isr Med Assoc J; 2008 Mar 10; 10(3):214-8. PubMed ID: 18494235
    [Abstract] [Full Text] [Related]

  • 25. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G, Gorini M, Maggioni AP, Di Lenarda A, Area Scompenso ANMCO, Firenze.
    G Ital Cardiol (Rome); 2007 Feb 10; 8(2):102-6. PubMed ID: 17402354
    [Abstract] [Full Text] [Related]

  • 26. Effects of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after hospital discharge on subsequent rehospitalization for acute myocardial infarction and heart failure.
    Hess G, Preblick R, Hill J, Plauschinat CA, Yaskin J.
    Congest Heart Fail; 2009 Feb 10; 15(4):170-5. PubMed ID: 19627290
    [Abstract] [Full Text] [Related]

  • 27. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.
    Dhaliwal AS, Bredikis A, Habib G, Carabello BA, Ramasubbu K, Bozkurt B.
    Am J Cardiol; 2008 Nov 15; 102(10):1356-60. PubMed ID: 18993155
    [Abstract] [Full Text] [Related]

  • 28. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 Nov 15; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
    Pietrasik G, Goldenberg I, McNitt S, Polonsky B, Moss AJ, Zareba W.
    J Cardiovasc Electrophysiol; 2009 Apr 15; 20(4):395-400. PubMed ID: 19017351
    [Abstract] [Full Text] [Related]

  • 30. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ, Gums JG.
    Ann Pharmacother; 2005 Mar 15; 39(3):470-80. PubMed ID: 15701766
    [Abstract] [Full Text] [Related]

  • 31. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function.
    Shah R, Wang Y, Foody JM.
    Am J Cardiol; 2008 Jan 15; 101(2):217-22. PubMed ID: 18178410
    [Abstract] [Full Text] [Related]

  • 32. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
    Richter B, Derntl M, Marx M, Lercher P, Gössinger HD.
    Am Heart J; 2007 Jan 15; 153(1):113-9. PubMed ID: 17174648
    [Abstract] [Full Text] [Related]

  • 33. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 15; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 34. Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors.
    Krum H, Haas SJ, Eichhorn E, Ghali J, Gilbert E, Lechat P, Packer M, Roecker E, Verkenne P, Wedel H, Wikstrand J.
    Eur Heart J; 2005 Oct 15; 26(20):2154-8. PubMed ID: 16014644
    [Abstract] [Full Text] [Related]

  • 35. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
    Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy C, Young JB, OPTIMIZE-HF Investigators and Coordinators.
    Am Heart J; 2007 Jan 15; 153(1):82.e1-11. PubMed ID: 17174643
    [Abstract] [Full Text] [Related]

  • 36. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G.
    J Hypertens; 2009 May 15; 27(5):941-6. PubMed ID: 19381108
    [Abstract] [Full Text] [Related]

  • 37. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB.
    J Hypertens Suppl; 2006 Mar 15; 24(1):S3-7. PubMed ID: 16601570
    [Abstract] [Full Text] [Related]

  • 38. Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis.
    Mantziari L, Guha K, Khalique Z, McDonagh T, Sharma R.
    Am J Cardiol; 2012 Jun 01; 109(11):1619-25. PubMed ID: 22465318
    [Abstract] [Full Text] [Related]

  • 39. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators.
    Am Heart J; 2006 May 01; 151(5):985-91. PubMed ID: 16644319
    [Abstract] [Full Text] [Related]

  • 40. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, Wander GS, Yap JJ, MacDonald MR, Xu CF, Chia YM, Shimizu W, ASIAN-HF investigators, Richards AM, Voors A, Lam CS.
    Lancet Glob Health; 2018 Sep 01; 6(9):e1008-e1018. PubMed ID: 30103979
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.